Matches in SemOpenAlex for { <https://semopenalex.org/work/W2516177362> ?p ?o ?g. }
Showing items 1 to 90 of
90
with 100 items per page.
- W2516177362 endingPage "1027" @default.
- W2516177362 startingPage "1021" @default.
- W2516177362 abstract "This phase I trial evaluated the toxicity profile and maximum tolerated dose of the combination between the marine derived cyclodepsipeptide plitidepsin and bevacizumab in advanced cancer patients. Thirteen patients were enrolled and treated with plitidepsin at three dose levels (2.8 mg/m2, n=3; 3.8 mg/m2, n=4; and 4.8 mg/m2, n=6) with a fixed dose of bevacizumab (10 mg/kg). Both agents were administered intravenously at D1 and D15 of a 28-day cycle. All 13 patients were evaluable for safety and toxicity. Dose-limiting toxicities occurred in two out of six patients treated at the maximum dose tested (plitidepsin 4.8 mg/m2 and bevacizumab 10 mg/kg) and consisted of grade 3 fatigue, grade 3 myalgia, and two grade 2/3 alanine aminotransferase increases lasting for more than 7 days or leading to subsequent cycle delay greater than 2 weeks (n=1 each). The recommended dose for the combination of plitidepsin with bevacizumab was 3.8 mg/m2 for plitidepsin and 10 mg/kg for bevacizumab every 2 weeks. Most frequent treatment-related adverse events were nausea, vomiting, fatigue, epistaxis, and headache. Relevant hematological toxicity was minimal. Objective disease responses were not observed; however, stable disease (>3 months) was observed in four patients with colorectal cancer, renal cancer, and cervical cancer. Combining plitidepsin with bevacizumab combination is feasible. Stable disease was the best response obtained." @default.
- W2516177362 created "2016-09-16" @default.
- W2516177362 creator A5010064853 @default.
- W2516177362 creator A5021624793 @default.
- W2516177362 creator A5025894247 @default.
- W2516177362 creator A5031446684 @default.
- W2516177362 creator A5034376000 @default.
- W2516177362 creator A5063737641 @default.
- W2516177362 creator A5078388793 @default.
- W2516177362 date "2016-11-01" @default.
- W2516177362 modified "2023-09-25" @default.
- W2516177362 title "Phase I dose-escalation study of plitidepsin in combination with bevacizumab in patients with refractory solid tumors" @default.
- W2516177362 cites W1964109435 @default.
- W2516177362 cites W1970304552 @default.
- W2516177362 cites W1983939149 @default.
- W2516177362 cites W1993685031 @default.
- W2516177362 cites W2029745149 @default.
- W2516177362 cites W2044358283 @default.
- W2516177362 cites W2050662664 @default.
- W2516177362 cites W2063993461 @default.
- W2516177362 cites W2118174014 @default.
- W2516177362 cites W2122430929 @default.
- W2516177362 cites W2141816218 @default.
- W2516177362 cites W2145224595 @default.
- W2516177362 cites W2156792347 @default.
- W2516177362 cites W2156906256 @default.
- W2516177362 cites W2170089147 @default.
- W2516177362 cites W2206507896 @default.
- W2516177362 cites W2289495176 @default.
- W2516177362 doi "https://doi.org/10.1097/cad.0000000000000409" @default.
- W2516177362 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27610894" @default.
- W2516177362 hasPublicationYear "2016" @default.
- W2516177362 type Work @default.
- W2516177362 sameAs 2516177362 @default.
- W2516177362 citedByCount "8" @default.
- W2516177362 countsByYear W25161773622018 @default.
- W2516177362 countsByYear W25161773622019 @default.
- W2516177362 countsByYear W25161773622020 @default.
- W2516177362 countsByYear W25161773622022 @default.
- W2516177362 countsByYear W25161773622023 @default.
- W2516177362 crossrefType "journal-article" @default.
- W2516177362 hasAuthorship W2516177362A5010064853 @default.
- W2516177362 hasAuthorship W2516177362A5021624793 @default.
- W2516177362 hasAuthorship W2516177362A5025894247 @default.
- W2516177362 hasAuthorship W2516177362A5031446684 @default.
- W2516177362 hasAuthorship W2516177362A5034376000 @default.
- W2516177362 hasAuthorship W2516177362A5063737641 @default.
- W2516177362 hasAuthorship W2516177362A5078388793 @default.
- W2516177362 hasConcept C121608353 @default.
- W2516177362 hasConcept C126322002 @default.
- W2516177362 hasConcept C197934379 @default.
- W2516177362 hasConcept C2776694085 @default.
- W2516177362 hasConcept C2777802072 @default.
- W2516177362 hasConcept C2780580376 @default.
- W2516177362 hasConcept C2780852908 @default.
- W2516177362 hasConcept C29730261 @default.
- W2516177362 hasConcept C71924100 @default.
- W2516177362 hasConcept C90924648 @default.
- W2516177362 hasConceptScore W2516177362C121608353 @default.
- W2516177362 hasConceptScore W2516177362C126322002 @default.
- W2516177362 hasConceptScore W2516177362C197934379 @default.
- W2516177362 hasConceptScore W2516177362C2776694085 @default.
- W2516177362 hasConceptScore W2516177362C2777802072 @default.
- W2516177362 hasConceptScore W2516177362C2780580376 @default.
- W2516177362 hasConceptScore W2516177362C2780852908 @default.
- W2516177362 hasConceptScore W2516177362C29730261 @default.
- W2516177362 hasConceptScore W2516177362C71924100 @default.
- W2516177362 hasConceptScore W2516177362C90924648 @default.
- W2516177362 hasIssue "10" @default.
- W2516177362 hasLocation W25161773621 @default.
- W2516177362 hasLocation W25161773622 @default.
- W2516177362 hasOpenAccess W2516177362 @default.
- W2516177362 hasPrimaryLocation W25161773621 @default.
- W2516177362 hasRelatedWork W1996898072 @default.
- W2516177362 hasRelatedWork W2081557631 @default.
- W2516177362 hasRelatedWork W2111792237 @default.
- W2516177362 hasRelatedWork W2262648772 @default.
- W2516177362 hasRelatedWork W2330828714 @default.
- W2516177362 hasRelatedWork W2368337335 @default.
- W2516177362 hasRelatedWork W2375265431 @default.
- W2516177362 hasRelatedWork W2377198612 @default.
- W2516177362 hasRelatedWork W2473035192 @default.
- W2516177362 hasRelatedWork W4289131813 @default.
- W2516177362 hasVolume "27" @default.
- W2516177362 isParatext "false" @default.
- W2516177362 isRetracted "false" @default.
- W2516177362 magId "2516177362" @default.
- W2516177362 workType "article" @default.